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Vegetable lipid emulsions (LE) contain non-declared phytosterols (PS). We aimed to determine 
PS content depending on the brand and LE batch; and in adult hospitalized patients treated with 
parenteral nutrition (PN), to establish the association between plasma and administered PS. 
I. LE study: Totals and fractions of PS in 3-4 non-consecutive batches from 6 LE were 
analysed. II. Patient study: randomized, double-blind study of patients with at least 7 previous 
days of PN with 0.8 g/kg/day of an olive/soybean LE, were randomized (Day 0) 1:1 to 
olive/soybean (O/S) or 100% fish oil (FO) at a dose of 0.4 g/kg/day for 7 days (Day 7).  Plasma 
PS, its fractions, total cholesterol on Days 0 and 7, their clearance, and their association with PS 
administered by LE were studied.  
In part I. LE study: differences were found in the total PS, their fractions and cholesterol among 
different LE brands and batches. Exclusive soybean LE had the highest content of PS (422.36 ± 
130.46 μg/mL). II. Patient study: 19 patients were included. In the O/S group, PS levels were 
maintained (1.11±6.98 μg/mL) from Day 0 to 7, while in the FO group, significant decreases 
were seen in total PS (-6.21±4.73 μg/mL) and their fractions, except for campesterol and 




PS content in different LE brands had great variability. PS administered during PN resulted in 
accumulation and could be prevented with the exclusive administration of FO LE. 
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The use of lipid emulsions (LE) in parenteral nutrition (PN) is a widespread practice. Their 
energy efficiency is high, their administration safe and the new generations of LE bring 
functional advantages; only in very specific cases are LE not administered when PN is required. 
Parallel to the development of new formulations that improve LE stability has been the 
increasing accumulation of knowledge in all fields of its use. 
First generation LE are 100% soybean oil and they have been used for decades. After that, next 
generation LE firstly included new formulations of 50% medium chain triglycerides (MCT) in 
combination with 50% long chain triglycerides (LCT) and a more efficient metabolic profile
1,2
; 
and secondly an 80:20 mix of olive oil and soybean oil with a high monosaturated fatty acid 
content, which is less prone to peroxidation than polyunsaturated fatty acids (PUFAs)
3
. Finally, 
the last development incorporated into the mix has been fish-oil (FO) based lipid emulsions 
(LE) used as a pharmaconutrient because of its anti-inflammatory activity
2,4,5
 and marketed 
either alone or in combination with other generation LEs. 
LE administration is not exempt from side effects, especially in certain clinical situations and in 
certain patient groups. Its use has been associated with hypertriglyceridemia, especially in septic 
patients, and pancreatitis and renal failure
6
 in patients who are under metabolic stress and have 
systemic inflammatory response syndrome (SIRS), which needs a high energy PN contribution. 
It has also been associated with alterations of liver function parameters in patients on long-term 
PN and in preterm infants, leading to parenteral-nutrition-associated liver disease (PNALD) 
with cholestasis or steatosis. 
Phytosterols (PS) have been noted as a factor associated with the alteration of liver function 
parameters and are therefore linked to PNALD
7–9
. PS are plant-derived sterols and undeclared 
components of vegetable origin in LE. Since all vegetable-origin LE contain PS and their 
content is not declared, the effect of their administration is unpredictable. PS content and their 
fractions in different LE have been analysed in a few studies
10
. Nevertheless the cumulative 
effect of PS and their plasma clearance are not clearly established, and neither is whether these 
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In this study, we present two complementary approaches aimed at determining the presence of 
PS and their fractions in commercial LE and in the plasma of patients treated with PN. This has 
been carried out in such a way that allows us later to study their association in the alteration of 
liver function parameters. 
The first objective of the study was to determine if the presence of cholesterol and PS – total 
content and their fractions – varied depending on the brand and different batches of LE. The 
second objective was to study, in hospitalized adult patients treated with continuous total PN, 
the association of plasma PS values – total content and their fractions – with the type and dose 





I. Study of lipid emulsions 
 A prospective observational study was conducted to determine the daily exposure to PS of 
patients treated with lipid PN, by quantification (μg/mL) of cholesterol, total PS and their 
fractions in commercialized intravenous LE available in the pharmaceutical market (Table 1). 
At least 3 batches, corresponding to non-consecutive manufacturing, of each one of the 5 
commercial preparations of vegetable origin LE were studied. The PS fractions studied in the 
LE were β-sitosterol, campesterol, lanosterol, and stigmasterol. Cholesterol contained in egg 
lecithin added to LE as an emulsifier was also studied. 
For the quantification of total PS and their fractions, an analytical method of high-performance 
liquid chromatography (HPLC) was developed. This method allowed us to separate PS from the 
matrix in a simple and efficient way, designed so that in a short time PS samples were obtained 
with a high percentage of extraction and good repeatability. Liquid chromatography was carried 
out in a Dionex Ultimate 3000 chromatograph, as published by our group
11
. PS analyses of the 
LE were carried out according to the "European Union Regulation (EEC) Number 2568/91" for 
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variation between the replicated analyses was determined. The sample preparation was adapted 
and modified (without derivation) using the methods previously described by Xu et al
12
. The 
tubes were purged with N2 and subjected to saponification at 100ºC for 1 h. Our sample size 
was established from the results obtained by Xu et al
12
 in their study on the amount of PS in 
different commercial preparations, in which the reproducibility among batches was greatly 
reduced for all fractions.  
We estimated, according to the different standard deviations referenced, a sample size of 3 
samples per batch for a power of 90% and an error of 5% and, given the characteristics, without 
estimated losses. To establish the differences between brands and batches of LE, the analysis of 
variance of one factor (ANOVA) was carried out using the post-hoc Scheffé test. 
 
II. Study in patients 
Plasma values of PS, their fractions, total cholesterol, their clearance and their association with 
those administered via LE were studied by means of a prospective, unicentric, randomized, 
double-blind study. The selected population corresponded to that included in a clinical trial 
designed to study the relationship between the type of LE used and the evolution of liver 
function (EudraCT Number: 2014-003597-17 www.clinicaltrialsregister.eu). We studied if, in 
patients with gamma glutamyltransferase (GGT) alteration associated with PN containing 
vegetable origin LE, the strategy of reducing the lipid dose by 50% by switching to an FO-based 
LE would reduce plasma levels of PS and GGT, and whether it is more effective and equally 
safe as a strategy of reducing the lipid by 50% while maintaining the same vegetal LE. The 
patients had received a minimum of 7 days of PN with a lipid intake of 0.8 g/Kg/day of a 
olive/soybean LE, until they were randomized to 2 LE groups (Day 0): olive/soybean vs 100% 
FO (omega-3 fatty acids, without PS) at a dose of 0.4 g/kg/day for a minimum of 7 days (Day 
7). 
To determine the plasma values of PS, blood samples were collected in 4 mL tubes of lithium 
heparin and kept cold at 2-8°C for up to one hour. They were centrifuged at 2000 g for 10 
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Measurements of different PS concentrations in the plasma were carried out using the UPLC-
ACQUITY TQD measurement system, which uses liquid chromatography of high and rapid 
resolution (UPLC) coupled to tandem mass spectrometry as a measurement principle (MS/MS). 
We worked in the reverse phase modality using a C18 UPLC column that allowed a faster and 
higher resolution of the chromatographic peaks. The mobile phase was composed of two 
solutions of ammonium acetate and 0.1% (v/v) formic acid, one in acetonitrile and the other in 
methanol, using a gradient elution. 
Plasma values of total PS, their fractions and cholesterol were measured on Days 0 and 7. The 
differences between olive/soybean and FO groups were calculated. Since the PS and cholesterol 
content of LE was known, total amount of PS, their fractions and cholesterol administered 
during the 7 days could be calculated. The PS plasma fractions studied were β-sitosterol, 
sitostanol, campesterol, lanosterol, and stigmasterol. In these plasma determinations one more 
fraction studied was sitostanol, since the developed plasma method was more precise than the 
one developed to study PS in LE. In addition, the plasma PS values and their fractions were 
adjusted for the amount of cholesterol, leading to the phytosterol cholesterol ratio:  
(phytosterol/cholesterol)*100. Analysis of plasma PS is included in Appendix I as a 
supplemental material  
Statistical analysis 
Continuous variables were expressed as mean and standard deviations and the categorical ones 
as percentages. To study the variation of plasma values between olive/soybean and FO groups, a 
student's t-test was applied. To establish the differences between the baseline values at Day 0 
and Day 7 in each group, means were compared by a paired samples t-test. Simple linear 
regression tests were applied to study the association between plasma values and administered 
amounts. The data were processed with the IBM SPSS 22.0 statistical package, and the level of 
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I. Study of lipid emulsions 
Contents of sterols in the studied LE are depicted in Table 2, as well as comparisons with the 
corresponding ANOVA. 
Statistical differences were found in the content of total PS, their fractions and cholesterol 
content among the different LE. Intralipid, exclusive soybean oil derived LE, had the highest 
total PS content (422.36 ± 130.46 μg/mL). 
Among PS fractions, β-sitosterol was found in greater amounts in all vegetable LE, although 
with variations between the different LE. Clinolenic (76.38%) and SMOFlipid (74.82%) had the 
highest percentage, followed by Lipofundin MCT/LCT (67.3%) and Lipoplus (67.4%); 
Intralipid had the lowest percentage (57.03%). Stigmasterol was found at its highest percentage 
in Intralipid (27.29%), followed by Lipofundin (21.81%) and Lipoplus (20.63%). Clinolenic 
(9.51%) and SMOFlipid (12.23%) had the lowest percentage. 
There were also differences between different batches of each vegetable LE. Lipofundin was the 
LE with the least stigmasterol and campesterol inter-lot differences. Clinolenic and SMOF 
showed no significant differences for stigmasterol.  
In Lipoplus, lanosterol was not detected in any of the batches analysed. In FO LE (Omegaven), 
as expected, no PS fractions were detected.  
Cholesterol percentages were very different between LE and different batches of each LE. 
Omegaven, SMOFlipid and Intralipid had high cholesterol content, while Lipofundin and 
Clinolenic had the lowest content. 
 
II. Study in patients: sterols plasma values 
We studied 19 patients, 73.7% men, 66.74 ± 11.39 years and 74.92 ± 15.00 kg. The mean 
number of days of PN administration prior to inclusion in the study was 9.47 ± 4.01, and during 
this period the patients received an olive/soybean LE at 0.8 g/kg/day. All patients had a 
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(n=4) cancer. The rest of patients suffered from one case of the following pathologies: 
adhesions, mesenteric ischemia, morbid obesity, occlusion and intestinal volvulus.  
Table 3 shows the baseline values of the patients on Day 0, when no statistically significant 
differences were found between the group of patients, neither in sterol plasma values nor in 
demographic parameters. 
Plasma PS levels on Days 0 and 7 had a normal distribution, according to the Kolgomorov-
Smirnov test (p=0.200). Table 4 shows sterol variations in the two study groups between Day 7 
and Day 0. Intragroup variation (t-student) and intergroup variation (t-pairs) were analysed. In 
the olive/soybean LE, a lipid dose reduction, from 0.8 g/kg/day to 0.4 g/kg/day for one week, 
was not associated with a significant decrease in total plasma PS or any of its fractions; this was 
also true for cholesterol. However, the change from a dose of 0.8 g/kg/day of olive/soybean LE 
to 0.4g/kg/day of FO LE for one week was associated with a statistically significant decrease in 
total PS and their fractions, except for sitostanol, campesterol, and stigmasterol. 
In the FO group, significant decreases in PS were seen while in the olive/soybean group PS 
levels were maintained. Additionally in the FO group, the most significant decreases during the 
7 days of the study were total PS 31.49%, β-sitosterol 55.70% and lanosterol 72.11%, while 
smaller decreases were seen with stigmasterol and campesterol at 45.07% and 20.73%, 
respectively. 
Table 5 shows the same temporal comparison as Table 4, adjusting total phytosterol values and 
their fractions for cholesterol by means of the phytosterol/cholesterol ratio. A decrease was 
seen compared with the values not adjusted for cholesterol. In the FO group, total PS adjusted 
for cholesterol decreased by 36.38%, while for those not adjusted the decrease was 31.49%. 
 
III. Plasma sterols according to the sterol content of the lipid emulsions administered 
Plasma PS on Day 7 were significantly associated with the amount of PS administered during 
the overall study period with a determination coefficient of R
2
=0.443 (Table 6). When studying 
the PS fractions, both β-sitosterol and lanosterol were significantly associated with the 
respective fractions administered, with high determination coefficients (R
2
) 0.657 and 0.557, 
respectively. Plasma levels of campesterol and stigmasterol showed no significant association 
with the amounts administered and showed a low coefficient of determination. Plasma 
cholesterol was also not associated with administered cholesterol and had low R
2
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I. Study of lipid emulsions 
There are few publications
10,12–14
 that study the content of PS in LE, despite the increasingly 
relevant evidence of the impact that PS have on hepatic damage. In this study, we show that the 
approach is not simple because of the significant differences in content between the different 
commercial brands of LE and, what is also relevant, between batches of the same commercial 
brand. 
In our study, we found that the differences in the amount of total PS (depending on the brand) 
were within the range described in an update to the American Society of Parenteral and Enteral 
Nutrition (ASPEN) position paper in 2014, which collected data from several studies
12–14
  





. The highest concentrations were of β-sitosterol, while 
campesterol and lanosterol had the lowest concentration, even though there were large 
variations depending on the brand. It has been described previously that stigmasterol is a potent 
antagonist of some families of hepatic nuclear receptors that trigger biliary disorders, contrary to 
what happens with β-sitosterol and campesterol, which have hardly any inhibitory effects on 
liver cells
16




As far as we know, there are no studies analysing interbatch differences in the sterol content in 
LE of the same brand. The variability between batches may have its origin in the quality of the 
oil source, associated with the geographical source, climate, year of harvest and also the 
extraction and refining process used. Some authors have reported that levels can be further 





II. Study in patients: sterol plasma values 
The values of plasma PS in our series of adult hospitalized patients after at least 7 days with PN 
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seen with 27 patients with home PN, and reported in our previous publication
18
, this was very 
similar to that found by Ellegard et al
9
 - 62.5±60.3 μg/mL - in 16 patients diagnosed with short 
bowel syndrome and treated with long-term PN.  
In the previous clinical randomized trial with the same population and design, we found a 
positive association between plasma values of PS (and their fractions) and values of GGT and 
ALT, whereas these associations were not seen in AP
19
. Now our results show that there is an 
accumulation of PS because their elimination is slower than the usual administration rate. In the 
group of patients that changed from 0.8 g to 0.4 g of olive/soybean LE, no reduction in 
administered plasma sterols was observed. On the other hand, in patients treated with FO LE 
(without PS), after 7 days an average reduction of 31.5% to the plasma concentration of 
13.51±5.16 μg/mL was observed, reaching values very close to those obtained in the healthy 
controls of our previous publication
18
 (14.8±2.3 μg/mL). It has been reported that plasma PS 
concentrations tend to remain stable in healthy individuals consuming conventional western 
diets, ranging from 3 to 17 μg/ml
20
, whereas in vegetarians and in patients with 




In animal models, PS levels increase rapidly following PN initiation, not only in serum, but also 
in the liver
8,22–24
. In a recent and interesting study in children with intestinal failure, Hukkinen et 
al.
 25
, through their linear regression model, showed total serum PS to be a robust indicator of 
accumulated PS liver levels (r=0.83, p<0.01 for absolute concentrations and r=0.98, p<0.01 for 
ratios to cholesterol) and associated with portal inflammation, biochemical liver injury, liver 






confirm that PS inhibit the farnesoid X receptor (FXR) by decreasing 
the transcription of target genes involved in the synthesis, uptake and excretion of bile acids, as 
well as in the excretion of sterol which is linked to cholestasis. Another complementary 
mechanism that would explain the role of PS in PNALD is the promotion of hepatic 
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which activate immune cell responses and promote cytokine production
22
. In a recent work, 
Guthrie et al
32
 concluded that PS alone are not the cause of liver inflammation, but that this 
occurs in conjunction with sepsis. The study reports that PS have a synergistic inflammatory 
effect with the experimental administration of lipopolysaccharides in Kupffer cells. 
A factor to take into account is the role of cholesterol, given that during PN administration the 
PS/cholesterol ratio is inverted with respect to the usual oral intake. PS in LE can displace 
cholesterol from cell membranes, which can decrease the elasticity of the tissue and contribute 
to the damage of hepatocytes
8,33
. As serum and liver sterol proportions are distorted during PN, 
with high PS and low cholesterol levels reflecting the lipid profile of PN solutions, the ratio of 
each PS fraction to cholesterol probably mirrors the metabolic effects of PS better than their 
absolute concentrations. In fact, in our series, when PS fractions were adjusted for cholesterol 
(Table 5), it was found that the clearance was greater in patients treated with FO. Besides, in 
the experimental study of Hukkinen et al
25
, plasma phytosterols ratio to cholesterol had a better 
correlation with the amount of phytosterols in liver tissue than absolute concentrations of 
phytosterols. 
β-sitosterol was the fraction with the highest concentration in LE administered to patients before 
starting the study, as well as in the olive/soybean LE group. It has been described that β-
sitosterol is secreted into bile more effectively than other PS fractions
34
, which possibly explains 
the greater β-sitosterol decrease compared with other fractions in the arm treated with FO. In 
their study Hukkinen et al
25
 explained the decrease in both plasma and hepatic PS after PN 
interruption. As in our plasma concentrations, in Hukkinen et al
25
 stigmasterol and campesterol 
in the liver did not differ when PN was suspended. In their study, serum and liver stigmasterol 
were not correlated, suggesting that these fractions are likely to be excreted at a slower rate. The 
same trend is seen in our series, where, after 7 days of PS administration (Table 6), the amount 
of stigmasterol administrated is not associated with its plasma values so pointing to a slower 
clearance. 
The clinical relevance of LE brand change has been suggested to improve liver function 
associated with a lower content of plasma PS as well as changes in the profile of PS fractions. In 
fact, some studies conducted in adult patients show that the transition from PN with soybean oil 
to olive oil improves intestinal-failure associated liver disease
28,35
, which can be partially 
explained by the different PS compositions of these LE, especially with stigmasterol which is 
reduced with the change of LE.  
Despite the experimental studies of Carter
16
 and El Kasmi
22
 proving stigmasterol as a powerful 
in vitro antagonist of FXR, superior to β-sitosterol and campesterol, there is no clear clinical 
evidence that stigmasterol itself presents greater hepatotoxicity than other fractions, so it cannot 
be confirmed that high stigmasterol LE are critical for the development of PNALD. However, 
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when changing brands from soybean exclusive LE to olive/soybean LE, is that a smaller 
stigmasterol content would lead to a greater (quicker) clearance of the total PS content. 
 
Study limitations: 
In the study of PS content of different LE brands, the accepted chromatographic method did not 
allow us to study small fractions of PS, thus prioritizing the implementation of a simple and 
accessible chromatographic method. 
A relevant limitation is that the sample selected corresponds to a substudy of a study designed 
to evaluate the utilization of FO LE in the improvement of previously altered liver function 
parameters. The method for selection of patients did not allow us to establish the basal values of 
PS, their fractions and cholesterol, before the beginning of the PN, nor to integrate the number 
of days treatment with PN on the day of onset. The only criterion was that the patients had had 
at least 7 days of PN. Another limitation was the small number of patients included with 
nutritional support over 7 days, only 3 cases, which did not allow us to establish statistically 
significant differences to evaluate cases with more than 7 days of PN, due to lack of statistical 




This study reveals the great variability in the sterol content of LE. The PS content, their 
fractions and cholesterol vary depending not only on the commercial brand but also between 
batches of the same commercial brand. In addition, the percentage of different PS fractions 
varies substantially from one brand to another, and is especially relevant in the case of 
stigmasterol. 
The amount of PS administered during PN exceeds the elimination, resulting in accumulation, 
and this varies depending on the fraction. The administration of FO LE exclusively (without PS) 
prevents accumulation. It is necessary to complement these data with clinical studies to evaluate 
the impact of PS levels and the possible therapeutic advantages of the administration of LE 
without PS. 
The results obtained highlight the importance of including the total PS concentration in the 
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Clinoleic (Baxter) 80% olive oil and 20% soybean oil 
Intralipid (Fresenius Kabi) 100% soybean oil 
Intralipid LCT/MCT 
(Braun) 
50% soybean oil and 50% MCT 
Lipoplus (Braun) 50% MCT, 40% soybean oil and 10% fish oil 
Omegaven (Fresenius Kabi) 100% fish oil  
SMOFlipid (Fresenius Kabi) 30% soybean oil, 30% MCT, 20% olive oil and 15% fish 
oil 
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Table 2. Total phytosterol content, fractions and cholesterol in different brand and batches  



















Clinoleic  20% 1 (n=3) 14H29N30 231.87±15.663  172.66±10.323 18.14±1.772,3 13.98±2.012 27.07±3.15 51.04±4.122  
 2 (n=6) 15F15N31 227.17±21.043 171.57±6.273 9.52±2.133  23.32±5.221,3 22.75±12.61  67.16±2.731,3  
 3 (n=3) 16F22N30 148.99±3.991,2 122.16±2.111,2  7.47±0.671 12.49±0.642 6.89±0.76 45.84±1.082 
 
Total (n=12)  208.80±39.52II,V,VI 159.49±23.35 II,IV,V,VI 11.16±4.60 II 18.28±6.42 
II,III,IV,V,VI 
19.87±11.79 II 57.80±10.29 II,V,VI 
*p value intrabatch   p<0.001  p<0.001 p<0.001 p=0.006 p=0.059 p<0.001 
Intralipid   1 (n=3) 10HB3671 451.34±23.242,3 276.54±2.213 32.66±3.892 13.21±0.583 128.92±17.773 360.92±7.093 
 2 (n=3) 10IK7012 554.10±36.491,3 283.03±17.123 99.97±6.611,3 13.09±0.913 158.00±12.383 368.68±23.503 
 3 (n=3) 10KC3584 261.64±12.851,2 163.10±9.131,2 32.89±0.902 6.84±0.371,2 58.81±2.521,2 212.20±10.881,2 
 Total (n=9)  422.36±130.46I,III,IV,V,VI 240.89±59.22I,III,IV,V,VI  55.17±33.82I,III,IV,V,VI 11.05±3.21 I,III,IV,V,VI 115.25±45.48I,III,IV,V,VI 313.94 ± 77.55I,III,IV,V 
*p value intrabatch   p<0.001 p<0.001 p<0.001 p<0.001  p<0.001  p<0.001 
Lipofundin   1 (n=3) 143638082 178.84±3.713 119.70±2.373 17.67±0.68 2.50±0.533 38.95±1.16 63.59±2.412,3 
MCT/LCT 2 (n=3) 144718082 189.75±9.37 125.63±4.533 19.88±1.73 1.82±0.02 42.42±3.73 82.88± 4.411 
 3 (n=3) 154818081 195.36±3.971 134.22±2.041,2 18.03±0.84 1.46±0.051 41.66±1.32 76.19±0.181 
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*p value intrabatch   p=0.045 p=0.004 p=0.123 p=0.016 p=0.250 p=0.001 
Lipoplus  1 (n=3) 144538082 145.88±6.062,3 102.10±4.953 17.29±0.592,3 0.00 26.47±0.792 182.48±8.913 
 2 (n=3) 153938083 160.53±1.501,3 107.88±1.193 19.48±0.411,3 0.00 33.16±0.491,3 176.22 ±4.173 
 3 (n=3) 160128082 113.78±1.611,2 73.25±0.391,2 13.47±0.521,2 0.00 27.06±0.882 112.73±0.401,2 
 Total (n=9)  140.06 ± 20.96 II,VI 94.41±16.27 I,II,VI 16.74±2.67 II 0.00I,II,V 28.90±3.27 II,VI 157.15±11.26 II,V,VI 
*p value intrabatch   p<0.001 p<0.001 p<0.001 -- p<0.001 p<0.001 
SMOFlipid   1 (n=3) 16IF1650 137.64±2.953,4 99.99±1.363,4 13.38±1.263,4 7.41±0.562,3,4 16.86±1.38 420.95±4.672,3,4 
 2 (n=3) 16HI2073 138.94±7.573,4 99.58±1.183,4 12.63±2.373,4 10.27±1.561,3,4 16.46±3.07 399.49±2.681,3,4 
 3 (n=3) 16IG1719 121.12±9.291,2,4 93.53±1.651,2,4 7.21±1.681,2 2.78±0.511,2 15.78±6.08 578.92±6.151,2,4 
 4 (n=3) 16KG5043 102.35±3.231,2,3 74.50±2.061,2,3 7.62±0.351,2 4.79±1.371,2 15.45±2.24 300.75± 13.411,2,3 
 Total (n=12)  124.23±15.28 II,VI 92.96±9.88 I,II,VI 9.61±3.21II 5.60±0.80 I,II,IV,VI 16.06 ± 3.9II,III,IV 455.80±112.39 I,II,III,IV 
*p value intrabatch   p<0.001 p<0.001 p<0.001 p<0.001 p=0.976 p<0.001 
Omegaven  1 (n=3) 16H60131 0.00 0.00 0.00 0.00 0.00 400.39±1.792,4 
 2 (n=3) 16IG1719 0.00 0.00 0.00 0.00 0.00 507.35± 4.421,3,4  
 3 (n=3) 16IE1319 0.00 0.00 0.00 0.00 0.00 408.67±8.902,4 
 4 (n=3) 16KF4268 0.00 0.00 0.00 0.00 0.00 348.23±3.421,2,3 
 Total (n=12)  0.00I,II,III,IV,V 0.00 I,II,III,IV,V 0.00 I,II,III,IV,V 0.00 I,II,III,IV,V 0.00 I,II,III,IV,V 416.16±60.25 I,III,IV 
*p value intrabatch   -- -- -- -- -- p<0.001 
**p value 
intrabrands 
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*   One factor ANOVA of one factor between batches of every fat emulsion, Snedeckor F and signification (p).     
** One factor ANOVA of one factor between fat emulsions, Snedeckor F and signification (p).      
Arabic numbers in superindex are the result of the posthoc Scheffé analysis between batches identified as 1, 2, 3 and 4 with p<0.05 for each fat emulsion  
p<0.05.  
Roman numbers in superindex are the result of the posthoc Scheffé analysis between LE identified as I Clinoleic; II Intralipid; III Lipofundin MCT/LCT;  IV, 
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Table 3. Demographics and baseline (Day 0) values of patients  
 
Parameter Olive/soy n=10 Fish oil n=9 P* 
Men, n (%) 9 (90%) 5 (56%) 0.089 
Age (years),   mean ±SD 65.7±13.58 67.88±8.29 0.681 
Weight (Kg),  mean ±SD 80.54±8.92 68.68±18.26 0.085 
Cholesterol  (µg/mL ),  mean ±SD 1022.96±261.26 954.76±389.83 0.657 
Total Phytosterol (µg/mL),  mean ±SD 22.19±6.40 19.72±6.61 0.420 
 
Day 0 means that the patients had received a minimum of 7 days of PN with a lipid intake of 0.8 
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Table 4. Variation of sterols between Day 0 and Day 7 
Sterols 
variation 
Patients with vegetable fat emulsion 
(n=10) 
Patients with fish oil (n=9) 
p* 
Initial values 











Phytosterols    22.190±6.40 1.11±6.98 19.72±6.61 -6.21±4.73 0.016 
(µg/mL) 23.300±6.91  13.51±5.16   
p**  0.621  0.004  
Β-Sitoesterol 13.12±4.11 0.67±5.08 11.50±2.97 -6.11±2.20 0.002 
(µg/mL)  13.79±4.67  5.39±2.05   
p**  0.685  0.000  
Sitostanol   0.36±0.15 -0.03±0.16 0.25±0.18 -0.11±0.10 0.223 
(µg/mL) 0.33±0.12  0.14±0.11   
p**  0.560  0.013  
Campesterol     2.24±0.69 0.01±0.53 1.93±0.95 -0.40±0.73 0.171 
(µg/mL) 2.25±0.68  1.53±0.68   
p**  0.940  0.136  
Lanosterol     1.19±0.68 -0.14±0.66 1.04±0.50 -0.74±0.46 0.035 
(µg/mL) 1.05±0.41  0.30±0.19   
p**  0.536  0.015  
Stigmasterol     0.67±0.34 0.01±0.44 0.69±0.53 -0.30±0.48 0.160 
(µg/mL) 0.68±0.44  0.39±0.28   
p**  0.933  0.101  
Cholesterol    1022.96±261.27 122.74±234.78 954.76±389.83 41.49±253.91 0.478 
(µg/mL) 1145.70±212.80  996.24±355.21   
P**  0.133  0.637  
*Significance between groups (p) for the variable differences (t-student) 
**Significance intra groups (p) for initial and final variables (t-pairs) 
Day 0 means that the patients had received a minimum of 7 days of PN with a lipid intake of 0.8 
g/Kg/day of an olive/soybean lipid emulsion. 
Day 7 means that the patients had received 7 days of PN with a lipid intake of 0.4 g/kg/day of 
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Table 5. Variation of plasma values of phytosterols and fractions adjusted by cholesterol 




Patients with vegetable fat emulsion  
(10) 
 
Patients with fish oil 
(9) 
P* 
 Initial values 












  R_Phytosterols 2.28±0.78 -0.25±0.64 2.16±0.48 -0.79±0.47 0.057 
(µg/mL) 2.02±0.50  1.37±0.34   
p**  0.243  0.001  
R_β-sitoesterol 1.35±0.51 -0.14±0.47 1.30±0.35 -0.74±0.35 0.006 
(µg/mL) 1.21±0.34  0.56±0.17   
p**  0.367  0.000  
R_Sitostanol 0.04±0.02 -0.01±0.01 0.03±0.02 -0.01±0.01 0.606 
(µg/mL) 0.03±0.01  0.01±0.01   
p**  0.119  0.019  
R_Campesterol 0.23±0.08 -0.03±0.41 0.20±0.05 -0.05±0.05 0.227 
(µg/mL) 0.20±0.06  0.15±0.04   
p**  0.067  0.012  
R_Lanosterol 0.12±0.08 -0.03±0.07 0.12±0.07 -0.09±0.06 0.061 
(µg/mL) 0.09±0.03  0.03±0.02   
p**  0.188  0.003  
R_Stigmasterol 0.07±0.04 -0.01±0.04 0.07±0.06 -0.03±0.06 0.301 
(µg/mL) 0.06±0.03  0.04±0.03   
p**  0.537  0.133  
*Significance between groups (p) for the variable differences (t-student) 
**Significance intra groups (p) for initial and final variables (t-pairs) 
R_ means the coefficient that results from dividing each phytosterol value by the value of 
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Table 6. Simple lineal regressions between plasma phytosterols on Day 7 (y) and 




 b1 CI (95%) p 
Phytosterol  0.443 0.007 0.003 – 0.011 0.002 
Β- sitoesterol  0.657 0.009 0.006 – 0.012 0.000 
Campesterol 0.093 0.003 -0.002 – 0.008 0.205 
Lanosterol 0.557 0.006 0.004 – 0.009 0.000 
Stigmasterol 0.066 0.001 -0.001 – 0.004 0.287 
Cholesterol 0.066 0.094 -0.331 – 1.051 0.287 
 
y=b0±b1x1; y: plasma phytosterols on day 7; x: phytosterols administered 
R
2
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